&lt;p&gt;MicroRNA-3651 promotes the growth and invasion of hepatocellular carcinoma cells by targeting PTEN&lt;/p&gt;

Zhao, Xinyang; Song, Qilong; Miao, Guowang; Zhu, Xike

doi:10.2147/ott.s213705

Cited by 5 publications

(5 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Conversely, decreased expression of this marker clearly led to inhibition of growth and invasion of this cell line by stimulation of apoptosis. As a result, this study suggested that miRNA3651 could be considered as a new therapeutic target in hepatocellular carcinoma (32).…”

Section: Discussionmentioning

confidence: 78%

“…It is located in the nucleus of a human cell on chromosome 9 (9q22.31) and is estimated to be 24 nucleotides in length. Changes in the expression of this miRNA have been studied in various cancers, including esophageal cancer (25), nasopharynx (29), liver cells (32) and colorectal (30,33). Also, according to articles that examined such biomarkers in precancerous lesions compared to cancerous and normal tissue, and observed changes in the incidence of these biomarkers (31), resulting in the possibility of changes in the expression of this miRNA in cancer.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

miRNA-3651: a Diagnostic Marker in Oral Squamous Cell Carcinoma?

Saeidmohamadi

Ghorbanpour

Jolehar

2021

Preprint

View full text Add to dashboard Cite

Background and aim: microRNAs are a group of small non-coding single-stranded RNAs that control post-transcriptional gene expression. They can act as oncogenes or tumor suppressors by amplifying or preventing the expression of certain genes. present study was conducted to assess the expression of miRNA-3651 in paraffin blocks of oral squamous cell carcinoma (OSCC) cells using qRT-PCR method in Islamic Azad university, dental branch of Tehran in 1399.Material and methods: This case-control study was conducted on 20 paraffin blocks of irritation fibroma (IF) as control group and 20 paraffin blocks of patients with oral squamous cell carcinoma as case group. After RNA extraction, qRT-PCR was performed. all experiments were repeated 3 times for each sample. Eventually the data were analyzed by SPSS 24 statistics software. Differences in miRNA expression levels between the two groups were compared using the independent samples t-test. In order to evaluate the correlation between mean levels of miRNA-3651 marker and different variables (grade, age and sex of patients), Kruskal-Wallis test, Pearson's correlation coefficient test and independent samples t-test were used, respectively.Results: The results showed that the mean expression of this biomarker method was 10.15± 5.44 rpm in normal tissue and 8.11± 1.57 rpm in cancerous tissue. Despite the lower expression of miRNA-3651 in cancerous tissue samples than normal samples, this decrease was not statistically significant (P> 0.05). There was no significant difference between the mean level of miRNA-3651 marker and different grades, age and sex of patients (p> 0.05).Conclusion: In the end, it seems that the evaluation of changes in the expression of miRNAs such as miRNA-3651, can be a minimally invasive method, in early detection and screening of patients with OSCC. Decreased expression of miRNA-3651 marker in cancerous tissue compared to normal tissue indicates the importance of these biomarkers, including miRNA-3651 in the diagnosis of oral cancer, and the researchers of this project suggest further and broader investigations on the mechanism of action and signaling cascades associated with this marker in oral cancer.

show abstract

Section: Discussionmentioning

confidence: 78%

Section: Discussionmentioning

confidence: 99%

miRNA-3651: a Diagnostic Marker in Oral Squamous Cell Carcinoma?

Saeidmohamadi

Ghorbanpour

Jolehar

2021

Preprint

View full text Add to dashboard Cite

show abstract

“…Additionally, FRMD3 was identified as a putative target that interferes with protein binding as well as cytoskeletal and cell membrane stability. While hsa-miR-3651 has been described as a discriminatory marker in other cancer types, such as head and neck [9,10], ovaries [11], colorectal [12], liver [13], lung [14] and nephroblastoma [30], the current analysis is the first in breast cancer. From the viewpoint of sample selection, the study by Tuncer can be regarded as related to ours, in as far as it also investigates hormone dependent tissue.…”

Section: Discussionmentioning

confidence: 99%

“…The significance of microRNAs for local control (LC) could be demonstrated in three previous publications [ 6 – 8 ]. While hsa-miR-3651 has been described in other cancer types such as head and neck [ 9 , 10 ], ovarian [ 11 ], colorectal [ 12 ], liver [ 13 ] and lung [ 14 ], the current study is the first to demonstrate its relevance in breast cancer. Thus far, no data are extant on its potential target proteins, let alone a potential pathway which it could interfere in.…”

Section: Introductionmentioning

confidence: 88%

Hsa-miR-3651 could serve as a novel predictor for in-breast recurrence via FRMD3

et al. 2021

View full text Add to dashboard Cite

Background MicroRNAs are small non-coding RNAs with pivotal regulatory functions in multiple cellular processes. Their significance as molecular predictors for breast cancer was demonstrated in the past 15 years. The aim of this study was to elucidate the role of hsa-miR-3651 for predicting of local control (LC) in early breast cancer. Results By means of high-throughput technology, hsa-miR-3651 was found to be differentially expressed between patients who experienced local relapse compared to those without (N = 23; p = 0.0035). This result could be validated in an independent cohort of 87 patients using RT-qPCR (p < 0.0005). In a second analysis step with a chip-based microarray containing 70,523 probes of potential target molecules, FERM domain protein 3 (FRMD3) was found to be the most down-regulated protein (N = 21; p = 0.0016). Computational analysis employing different prediction algorithms revealed FRMD3 as a likely downstream target of hsa-miR-3651 with an 8mer binding site between the two molecules. This could be validated in an independent patient set (N = 20, p = 0.134). Conclusion The current study revealed that hsa-miR-3651 is a predictor of LC in early breast cancer via its putative target protein FRMD3. Since microRNAs interfere in multiple pathways, the results of this hypothesis generating study may contribute to the development of tailored therapies for breast cancer in the future.

show abstract

“…Over the past few years, Zhu et al have discovered aberrant increase of miR-3651 in HCC cases through microarray analysis of microRNA [ 10 ]. Zhao et al have confirmed the function of miR-3651 in promoting the growth and invasion of HCC cells through targeting PTEN [ 11 ]. The above can confirm the crucial role of miR-3651 in HCC.…”

Section: Introductionmentioning

confidence: 99%

miR-3651 Participates in the Growth Cycle of Hepatocellular Carcinoma Cells and Promotes the Malignant Metastasis via the PI3K/AKT/mTOR Signalling Pathway

Liu

et al. 2022

Journal of Oncology

View full text Add to dashboard Cite

Objective. Hepatocellular carcinoma (HCC) shows a growing incidence over the past few years, and clinical efforts are made to search for more effective novel diagnosis and therapy regimen for it to improve its outcome. This study probed into the association of miR-3651 with the PI3K/AKT/mTOR pathway to offer a more detailed reference to the follow-up exploration of novel diagnosis and therapy methods of HCC. Methods. Totally, 83 patients with HCC treated in our hospital between Apr. 2017 and Aug. 2018, 100 patients with simple liver cirrhosis (LC), and 94 normal persons over the same time span were enrolled, and serum miR-3651 in them was quantified to understand the predictive and prognostic significance of miR-3651 for HCC. In addition, with purchased human HCC cell strains (HepG2), the impacts of miR-3651 on the invasion as well as proliferation of HepG2 were determined using the MTT and Transwell assays, and the PI3K/AKT/mTOR pathway and autophagy-associated proteins in HepG2 were quantified via WT. Results. Serum miR-3651 was found to be higher in HCC patients than in LC patients and normal persons, and it presented a sensitivity and specificity of 57.14% and 94.00%, respectively, in forecasting the occurrence of HCC in LC patients. The decrease of miR-3651 in HCC patients after therapy was strongly bound up with patients’ prognosis, and its increase implied an increased risk of death. In in vitro assays, HepG2 presented higher miR-3651 expression than HL-7702, and upregulated miR-3651 intensified the invasion and proliferation of HepG2, while silencing miR-3651 gave rise to opposite results. Additionally, the PI3K/Akt/mTOR pathway in HepG2 presented an obvious activation state, and its activation was further intensified after increase of miR-3651, while its activation was suppressed after silence of miR-3651. Moreover, HepG2 presented notably downregulated autophagy-associated proteins, and the increase of miR-3651 further suppressed the autophagy process, but with the intervention of BEZ235, the impacts of miR-3651 were completely reversed. Conclusion. miR-3651 intensifies the growth and invasion of HCC cells through activating the PI3K/AKT/mTOR signalling pathway, which is probably a breakthrough in the future diagnosis and therapy of HCC.

show abstract

<p>MicroRNA-3651 promotes the growth and invasion of hepatocellular carcinoma cells by targeting PTEN</p>

Cited by 5 publications

References 26 publications

miRNA-3651: a Diagnostic Marker in Oral Squamous Cell Carcinoma?

miRNA-3651: a Diagnostic Marker in Oral Squamous Cell Carcinoma?

Hsa-miR-3651 could serve as a novel predictor for in-breast recurrence via FRMD3

miR-3651 Participates in the Growth Cycle of Hepatocellular Carcinoma Cells and Promotes the Malignant Metastasis via the PI3K/AKT/mTOR Signalling Pathway

Contact Info

Product

Resources

About